Healthcare has no shortage of successful AI pilots. What it lacks is a repeatable way to turn those pilots into enterprise value.
Health systems are deploying ambient documentation, predictive models, generative AI, revenue cycle automation, and increasingly AI agents across clinical and administrative workflows.
Yet an important question remains:
Why do so many promising AI pilots still struggle to become sustainable enterprise capabilities? The answer is not simply that healthcare needs better technology.
In my experience leading AI initiatives across payer and provider organizations, the larger problem is what I call the AI Value Gap: the distance between demonstrating that an AI solution works and proving that it can repeatedly create measurable value in real-world operations.
Most organizations have become increasingly proficient at the first part of the journey:
Idea → data → model → validation → pilot
But enterprise value is created on the other side:
Production → workflow → adoption → outcomes → scale
Crossing that gap requires a very different set of organizational capabilities.
A successful pilot answers only one question
Pilots are important. They allow organizations to test assumptions, evaluate technologies, and determine whether an idea deserves further investment.
But pilots operate under unusually favorable conditions. They often have enthusiastic champions, dedicated technical resources, narrow populations, close vendor support, and heightened executive attention. Problems are resolved quickly because everyone involved wants the initiative to succeed. Enterprise deployment removes many of those advantages.
Now the solution must work across departments, locations and user populations. Data pipelines must operate reliably. Integration cannot depend on manual intervention. Users need support. Governance must continue after approval. Models must be monitored. Workflows evolve. Costs accumulate. And someone must remain accountable when the original project team moves on. That is why leaders should distinguish between two very different questions:
Pilot question: Can the technology work?
Scale question: Can the organization operate it repeatedly, reliably, and economically?
A “yes” to the first does not guarantee a “yes” to the second.
The five tests of scalable AI
Rather than treating a successful pilot as evidence that an initiative should automatically move into production, healthcare organizations should require AI initiatives to pass five additional tests.
1. The value test: is the problem important enough to solve?
Not every technically successful AI initiative deserves to scale.
Healthcare organizations have finite capital, integration capacity, clinical attention, and technology resources. Every AI initiative competes with other priorities.
The first question therefore should not be, “Did the model work?” It should be, “Is the problem valuable enough to justify enterprise deployment?” That value does not always have to be financial.
An AI solution may reduce clinician burden, improve patient access, create workforce capacity, strengthen quality, or reduce safety risk. But the expected outcome should be explicit before the pilot begins.
This requires identifying a business or clinical owner — not simply a technology sponsor — who remains accountable for the outcome.
As health systems expand their AI portfolios, the number of applications itself should not be viewed as a measure of success. What matters is whether those applications survive rigorous evaluation and deliver demonstrable value.
2. The workflow test: will people actually work differently?
In my previous Becker’s article, I argued that healthcare AI fails without workflow redesign. The same principle becomes even more important when moving from pilot to scale.
Before scaling an AI solution, leaders should be able to answer four questions: Who receives the AI output? Where does it appear? What decision does it support? And what will someone do differently because it exists?
If those answers are unclear, the organization may have validated a model without designing a scalable solution.
The critical question isn’t where to put the AI. It is what work will change because AI exists.
3. The production test: can we operate it reliably?
A prototype and a production AI system are fundamentally different products.
Production AI requires reliable data pipelines, security, access controls, integration, monitoring, incident management, versioning, and technical ownership.
Predictive AI introduces questions about data drift and model performance.
Generative AI adds challenges around grounding, factuality, changing foundation models and evaluation.
Agentic AI raises the stakes further because systems increasingly move from recommending to generating to acting.
Organizations therefore need to design for operationalization before the pilot succeeds — not afterward.
One useful question is, “If this pilot became available to 10,000 users tomorrow, what would break?” The answer often reveals whether an organization has built a demonstration or an enterprise capability.
4. The ownership test: who owns the AI after go-live?
This may be one of the most underestimated barriers to scale.
AI systems require lifecycle ownership. Someone must remain responsible for technical performance. Someone must own the workflow. Someone must monitor adoption. And someone must remain accountable for whether the original business case is being realized.
Those responsibilities should not default entirely to the data science or IT team. Scalable AI requires three forms of ownership:
Technical ownership: Is the system reliable, secure, and performing as expected?
Operational ownership: Is it still improving the workflow it was designed to support?
Value ownership: Is it producing the clinical, operational, or financial outcome that justified the investment?
These three owners do not necessarily need to be three different people, but all three responsibilities need to be explicit. Without that accountability, an organization can accumulate AI systems that remain technically “live” long after their operational value has diminished. Go-live therefore should not mark the end of an AI project. It should mark the beginning of AI lifecycle management.
5. The repeatability test: can we scale the capability, not just the use case?
This is where healthcare organizations should set a higher bar. Scaling AI does not simply mean deploying the same tool to more users. True enterprise scale means that the organization becomes better at deploying the next AI solution. After several successful implementations, leaders should ask,
“Did we develop reusable integration patterns? Did governance become faster because risk tiers were established? Can teams reuse data pipelines and monitoring infrastructure? Did product and clinical teams become better at redesigning workflows? Are evaluation methods becoming standardized? Can leaders compare competing AI investments using a common value framework?”
If every new AI initiative requires rebuilding these capabilities from scratch, the organization may be scaling applications — but it is not necessarily scaling AI. The real test of AI scale is not whether an organization can deploy one solution broadly. It is whether each deployment makes the next one easier.
The goal should be to reduce the marginal organizational effort required to move each subsequent high-value AI solution into production. That is the difference between having AI projects and having an enterprise AI capability.
Scaling also means knowing when to stop
There is another dimension of AI maturity that healthcare leaders should embrace: Stopping a pilot can be a success.
A pilot may demonstrate strong technical performance while revealing that integration costs are too high, adoption is too low, the workflow problem was misunderstood, or another solution can deliver greater value. Mature organizations should be willing to stop those projects.
One sign of AI maturity is not how many pilots an organization scales, but how quickly it identifies and stops the ones that should not scale. This suggests a healthier measure of AI maturity.
Do not ask,”How many pilots did we launch?” Ask, “How quickly can we identify which initiatives deserve to scale — and which should stop?”
The objective should not be to maximize the number of AI projects. It should be to maximize the value created by the AI portfolio.
From stage gates to an enterprise AI flywheel
Organizations can operationalize these principles by creating explicit stage gates:
Pilot: Does it work? → Value: Is the problem worth solving? → Workflow: Will people work differently? → Production: Can we operate it reliably? → Adoption: Are people using it? → Outcomes: Did the expected result occur? → Scale: Can the value be replicated?
But mature organizations should not view this as a one-way pipeline. Every implementation should make the next implementation easier. Governance decisions create reusable standards, and integration creates reusable architecture.
Monitoring creates reusable operational infrastructure, and workflow redesign builds organizational expertise.
Outcome measurement improves portfolio prioritization. Lessons from production feed back into the next use case.
Over time, the pipeline becomes an enterprise AI flywheel:
Deploy → Learn → Standardize → Reuse → Scale
Stage gates help organizations decide what deserves to scale. The flywheel helps them become better at scaling it. That is the transition healthcare organizations ultimately need to make.
The next measure of AI maturity
Healthcare’s AI conversation is already changing. Organizations are moving beyond isolated experiments toward enterprise deployments and increasingly treating AI as part of the health system’s operating model.
The next measure of maturity should therefore not be how many AI pilots an organization has launched — or even how many models it has put into production.
It should be whether the organization has developed a repeatable capability for converting AI into value. Can it identify the right problems?Can it stop the wrong ones? Can it integrate AI into workflows? Can it operate AI reliably? Can it measure adoption and outcomes? Can it reuse what it learns? And can it do all of this faster and more effectively with each successive deployment?
If the answer is yes, the organization has crossed the AI value gap. It is no longer simply experimenting with artificial intelligence. It has built the organizational capability to turn AI into value — repeatedly.
Executive takeaways
- A successful pilot proves AI can work; it does not prove the organization can scale it.
- Apply five tests before scaling: value, workflow, production, ownership, and repeatability.
- Design for production and ownership from the beginning. Infrastructure, integration, governance, monitoring, and lifecycle accountability cannot be afterthoughts.
- Normalize stopping pilots. AI maturity is demonstrated by disciplined investment decisions, not project counts.
- Scale capabilities, not just applications. Every deployment should make the next one easier.
Dr. Yapalparvi is an executive leader in artificial intelligence, machine learning, and healthcare analytics with more than 15 years of experience leading enterprise AI strategy and production-scale AI initiatives across payer and provider organizations. He has led multidisciplinary teams and initiatives spanning payment integrity, hospital-at-home, remote patient monitoring, clinical and operational decision support, revenue cycle analytics, MLOps, and generative AI.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
